[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368317-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368317-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","deletion-of-eno1-sensitizes-pancreatic-cancer-cells-to-gemcitabine-via-mycrrm1-mediated-glycolysis","Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis","","Glycolysis is crucial for pancreatic cancer cell energy, biosynthesis, redox balance, and survival. Alpha-enolase (ENO1) promotes tumor progression by driving glycolysis. This study links ENO1 to glycolysis activity and gemcitabine sensitivity in pancreatic cancer by analyzing ENO1 expression in tumors and modulating ENO1 in cell lines. ENO1 overexpression reduces gemcitabine sensitivity, while ENO1 silencing decreases glycolysis and enhances gemcitabine susceptibility. ENO1 regulates gemcitabine-resistance genes, especially RRM1, through a MYC-dependent glycolytic pathway, supporting its role in progression and chemoresistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deletion-of-eno1-sensitizes-pancreatic-cancer-cells-to-gemcitabine-via-mycrrm1-mediated-glycolysis/368317/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deletion-of-eno1-sensitizes-pancreatic-cancer-cells-to-gemcitabine-via-mycrrm1-mediated-glycolysis/368317.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does ENO1 play in pancreatic cancer metabolism and drug response?","Question",{"text":63,"@type":64},"ENO1 promotes glycolysis, supporting pancreatic cancer cell survival and contributing to reduced sensitivity to gemcitabine.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do ENO1 overexpression and ENO1 silencing affect gemcitabine sensitivity?",{"text":68,"@type":64},"ENO1 overexpression decreases gemcitabine sensitivity and increases proliferation, migration, and invasion, while ENO1 silencing lowers glycolysis and increases gemcitabine sensitivity.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links ENO1-driven glycolysis to gemcitabine resistance?",{"text":72,"@type":64},"ENO1 regulates gemcitabine resistance-related genes, particularly RRM1, through a MYC-dependent glycolytic pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368317,1791096429,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDeletion of ENO1 sensitizes pancreatic cancer cells to gemcitabinevia MYC/RRM1-mediated glycolysis  \nYingpeng Lu1,2, Hongqin Ma2, Xiaoxiao Xiong2,3, Yusheng Du2, Li Liu2, Ji Wang2􀀍 & Wenxing Zhao2􀀍  \nGlycolysis is a critical metabolic pathway in cancer cells, fulfilling their energy requirements, supporting biosynthesis, maintaining redox balance, and enabling survival in hostile environments. Alpha-enolase (ENO1) has been identified as a key promoter of tumor progression through its involvement in glycolysis. This study aims to elucidate the relationship between ENO1, glycolysis, and gemcitabine sensitivity in pancreatic cancer (PC) . The expression levels of ENO1 in PC were analyzed using the GEPIA2 database, Kaplan-Meier survival plots, and immunohistochemistry (IHC) . To assess the impact of ENO1 on gemcitabine sensitivity, we manipulated ENO1 expression in PC cell lines through overexpression and silencing techniques. Subsequent analyses included flow cytometry assays, glucose uptake and lactate production measurements, and cytotoxicity assays. The underlying mechanisms by which ENO1 modulates gemcitabine sensitivity were explored using Western blotting (WB) . ENO1 was found to be significantly overexpressed in PC tissues, and elevated ENO1 levels were associated with poorer prognosis in PC patients. Overexpression of ENO1 reduced the sensitivity of PC cells to gemcitabine, enhancing cell proliferation, migration, and invasion by altering the cell cycle and inhibiting apoptosis. Conversely, silencing ENO1 decreased glycolysis in PC cells and heightened their sensitivity to gemcitabine. Furthermore, glycolysis inhibition—achieved through ENO1 knockdown, glucose deprivation, or treatment with 2-Deoxy-D-glucose (2-DG)—further enhanced the susceptibility of PC cells to gemcitabine. Mechanistically, ENO1 was found to regulate the expression of gemcitabine resistance-related genes, particularly ribonucleotide reductase catalytic subunit M1 (RRM1), via MYC through the glycolytic pathway, thereby contributing to gemcitabine resistance. This study demonstrates that ENO1 plays a crucial role in PC progression and is closely linked to gemcitabine resistance through its regulation of the glycolytic pathway.  \nKeywords ENO1, PC, Glycolysis, Gemcitabine sensitivity, RRM1  \nAbbreviations  \nENO1 Alpha-enolase PC Pancreatic cancer  \nIHC Immunohistochemistry  \nWB Western blot  \n2-DG 2-Deoxy-D-glucose  \nRRM1 Ribonucleotide reductase regulatory subunit M1 PFS Progression-free survival  \nDFS Disease-free survival  \nOS Overall survival  \nCR Complete remission  \n2-PGA 2-phosphoglycerate  \n1Department of General Surgery, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, No. 77, Chang’an South Rd, Zhangjiagang 215600, Jiangsu, China. 2Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, No.99, Huaihai West Rd, Xuzhou 221006, Jiangsu, China. 3Department of General Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, No 138, Huanghe South Rd, Suqian 223800, Jiangsu, China. 􀀍 email: [drwangji@gmail.com](drwangji@gmail.com); [wxzhaosurgy@163.com](wxzhaosurgy@163.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nPEP Phosphoenolpyruvate  \nFBS Fetal bovine serum  \nshRNA Short hairpin RNAs  \nc-MYC Human Myc proto-oncogene protein IC50 The half-maximal inhibitory concentration dNTP Deoxyribonucleotide  \nYAP1 Yes-associated protein 1  \nPC is a highly malignant gastrointestinal tumor with a poor prognosis and is the seventh leading cause of cancer-related mortality1,2. Radical resection remains the only potential cure for this fatal disease; however, most patients have already lost the opportunity for surgical resection by the time of diagnosis. Additionally, patients who undergo surgical resection often experience recurrence and metastasis within two years, resulting i","cbCaioWTgSETkIug","https://ap.wps.com/l/cbCaioWTgSETkIug","pdf",9232516,13,"English","# Introduction\n## Gemcitabine resistance and poor clinical outcomes\n## Glycolysis and the Warburg effect in pancreatic cancer\n## ENO1 as a glycolytic driver","[{\"question\":\"What role does ENO1 play in pancreatic cancer metabolism and drug response?\",\"answer\":\"ENO1 promotes glycolysis, supporting pancreatic cancer cell survival and contributing to reduced sensitivity to gemcitabine.\"},{\"question\":\"How do ENO1 overexpression and ENO1 silencing affect gemcitabine sensitivity?\",\"answer\":\"ENO1 overexpression decreases gemcitabine sensitivity and increases proliferation, migration, and invasion, while ENO1 silencing lowers glycolysis and increases gemcitabine sensitivity.\"},{\"question\":\"What mechanism links ENO1-driven glycolysis to gemcitabine resistance?\",\"answer\":\"ENO1 regulates gemcitabine resistance-related genes, particularly RRM1, through a MYC-dependent glycolytic pathway.\"}]","Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis | PDF",1790176264,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97f9097c44d146d4638bf18cfb923657.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/770c3b920410ae69e42a1951c8f73ee3.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7f4d2a42a06a3854997d74cd25907f9.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/118ba7e9c90b0a5b187dbdeaf63c7753.webp",980,1287]